Table 1 Clinical and biologic... | American Society of Hematology

Table 1

Clinical and biologic characteristics of the 111 patients with de novo AML

Patient no.	Sex	TET2 alterations	Karyotype	NPM1	FLT3-ITD	OS, mo	DFS, mo
1	Male	p.Gln417X	Not informative	Mutation	Negative	Not done	Not done
2	Male	p.Cys784X	46,XY	Wild-type	Positive	22+	21+
3	Female	p.Gly1313X	46,XX,del(15)(q1?4;q2?2)	Mutation	Positive	31+	7
4	Male	p.Arg1516X	46,XY	Mutation	Negative	23+	22
5	Male	p.Tyr2001X	46,XY	Wild-type	Negative	18+	17+
6	Female	p.[Ser1292Arg]+[Ala1355X]	46,XX,t(3;5)(q25;q34)	Wild-type	Negative	49+	21+
7*	Male	p.[Pro101His]+[Gln690X]	46,XY	Mutation	Positive	22+	21+
8	Male	p.Leu1637fs	46,XY	Wild-type	Negative	14+	4
9	Female	p.Asn1156fs	46,XX	Mutation	Negative	18	14
10	Female	p.[Val1199Ile]+[Glu1437fs]	46,XX,t(4;11)(q?;q1?),del(7)(q2?1)	Mutation	Negative	9	6
11	Male	p.G613fs	46,XY	Mutation	Negative	53+	17
12	Female	p.[Cys1271Trp]+[Asp1830fs]	46,XX	Mutation	Negative	13	1
13	Female	p.[L226Rfs]+[Gly1370Val]	Not informative	Mutation	Positive	6	3
14	Male	p.Gly1282Asp	46,XY	Mutation	Positive	10+	9+
15*	Male	p.Thr492Ser	46,XY	Mutation	Negative	11	8
16*†	Female	p.Ser282Phe	46,XX	Wild-type	Negative	9	8
17*†	Male	p.Ser282Phe	47,XY,t(8;21)(q22;q22),+der(8)t(8;21)	Wild-type	Negative	6+	4+
18*	Female	p.[Gln548Leu]+[Phe1368Tyr]	46,XX	Wild-type	Positive	11	7
19*	Male	p.Gly773Val	46,XY,inv(16)(p13q22)	Wild-type	Negative	38+	37+
20	Female	Deletion	Not informative	Wild-type	Negative	34+	34+

Patient no.	Sex	TET2 alterations	Karyotype	NPM1	FLT3-ITD	OS, mo	DFS, mo
1	Male	p.Gln417X	Not informative	Mutation	Negative	Not done	Not done
2	Male	p.Cys784X	46,XY	Wild-type	Positive	22+	21+
3	Female	p.Gly1313X	46,XX,del(15)(q1?4;q2?2)	Mutation	Positive	31+	7
4	Male	p.Arg1516X	46,XY	Mutation	Negative	23+	22
5	Male	p.Tyr2001X	46,XY	Wild-type	Negative	18+	17+
6	Female	p.[Ser1292Arg]+[Ala1355X]	46,XX,t(3;5)(q25;q34)	Wild-type	Negative	49+	21+
7*	Male	p.[Pro101His]+[Gln690X]	46,XY	Mutation	Positive	22+	21+
8	Male	p.Leu1637fs	46,XY	Wild-type	Negative	14+	4
9	Female	p.Asn1156fs	46,XX	Mutation	Negative	18	14
10	Female	p.[Val1199Ile]+[Glu1437fs]	46,XX,t(4;11)(q?;q1?),del(7)(q2?1)	Mutation	Negative	9	6
11	Male	p.G613fs	46,XY	Mutation	Negative	53+	17
12	Female	p.[Cys1271Trp]+[Asp1830fs]	46,XX	Mutation	Negative	13	1
13	Female	p.[L226Rfs]+[Gly1370Val]	Not informative	Mutation	Positive	6	3
14	Male	p.Gly1282Asp	46,XY	Mutation	Positive	10+	9+
15*	Male	p.Thr492Ser	46,XY	Mutation	Negative	11	8
16*†	Female	p.Ser282Phe	46,XX	Wild-type	Negative	9	8
17*†	Male	p.Ser282Phe	47,XY,t(8;21)(q22;q22),+der(8)t(8;21)	Wild-type	Negative	6+	4+
18*	Female	p.[Gln548Leu]+[Phe1368Tyr]	46,XX	Wild-type	Positive	11	7
19*	Male	p.Gly773Val	46,XY,inv(16)(p13q22)	Wild-type	Negative	38+	37+
20	Female	Deletion	Not informative	Wild-type	Negative	34+	34+

AML indicates acute myeloid leukemia; OS, overall survival; and DFS, disease-free survival.

Missense mutations located outside the conserved domains.

Recurrent mutation.